Overview of Celepid 10%

Property	Description
Active Ingredient	Soybean Oil (source of Fat/Triglycerides), Glycerol, Lecithin
Form	Sterile Intravenous Emulsion (10% concentration)
Pharmacological Class	Nutritional Supplement, Parenteral Nutrition Component
General Use	Source of Calories and Essential Fatty Acids
Origin	Natural (Soybean Oil and Lecithin)

What Type of Medicine is Celepid 10%?

Celepid 10% is a Nutritional Supplement classified as a Parenteral Nutrition Component, specifically a Sterile Emulsion prepared for Intravenous (I.V.) administration. This combination product is defined as an I.V. Fat Emulsion, a pharmacological class used for providing calories and essential fatty acids. It is utilized when a patient's nutritional needs cannot be met through oral or enteral feeding routes, a scenario encountered in critically ill patients or those undergoing major abdominal surgery.

The emulsion format is necessary for the safe delivery of fat-soluble nutrients directly into the bloodstream without causing harm. Its function is to supply a concentrated source of energy and essential fats.

Composition of Celepid 10%: Ingredients and Origin

The 10% concentration of Celepid is principally composed of Soybean Oil, Glycerol (Glycerin), and the emulsifier Lecithin (Phospholipids). The primary active ingredient, Soybean Oil, is a natural source of Fat (Neutral Triglycerides) and critical Essential Fatty Acids (EFAs), such as Linoleic Acid and alpha-Linolenic Acid. Glycerol contributes to the caloric intake and helps maintain the tonicity of the solution.

Lecithin (Phospholipids) is derived from natural sources and acts as a stabilizing agent. Soybean-based lipid emulsions are used to correct essential fatty acid deficiency.

Why is Intravenous Fat Emulsion Used for Nutritional Support?

The overall purpose of I.V. Fat Emulsion is to provide a complete caloric foundation for patients requiring long-term nutritional support. The preparation delivers highly energy-dense fats and glycerol, sustaining basic metabolic functions and energy levels. This support is recognized for its role in preventing tissue breakdown and maintaining cell membrane integrity. Furthermore, Celepid 10% serves the role of delivering Essential Fatty Acids to prevent nutritional deficiencies when fats are missing from the diet.

What side effects are possible with Celepid 10%?

Possible Side Effects and Safety Information

The official regulatory safety profile for Celepid 10% (Intravenous Fat Emulsion 10%) classifies possible effects by frequency and the body systems involved. The general principle governing this class of medicine is that common reactions are usually systemic and mild, while serious reactions relate to fat metabolism or prolonged administration.

Adverse Reaction Classification

Adverse Reaction Type	Examples from Regulatory Documentation
Common Reactions	Nausea, Vomiting, Fever/Pyrexia, Chills, Hyperlipidemia (high fat levels in the blood), Headache, and Pain/Irritation at the administration site.
System-Organ Classes	Effects documented across Hepatobiliary Disorders (e.g., Jaundice), Metabolism and Nutrition Disorders, and Blood and Lymphatic System Disorders (e.g., Thrombocytopenia).

Serious Safety Considerations

The official labeling documents rare, serious reactions and specific safety constraints:

Fat Overload Syndrome: A potentially severe, though rare, reaction associated with impaired clearance of fat, characterized by fever, changes in liver size, and blood cell abnormalities.
Hepatobiliary Disorders: Disorders like Parenteral Nutrition-Associated Liver Disease (PNALD) are associated with prolonged administration (use extending beyond two weeks).
Safety Constraints: The medicine is strictly contraindicated in patients with a known hypersensitivity to egg, soybean, or peanut protein, or in those with severe disorders of lipid metabolism, such as severe hypertriglyceridemia.
Population-Specific Notes: Neonates and Infants are noted to be at increased risk of aluminum toxicity and PNALD, necessitating careful monitoring due to their slower clearance of the emulsion.

Routine monitoring of serum triglycerides and liver function tests is a mandated regulatory safety requirement to detect these adverse changes early. Reactions like flushing and dyspnea may occur during the initial administration of the infusion.

Overdose and Emergency Response

Overdose and when to seek help

The officially documented manifestation of overdose for this intravenous fat emulsion is Fat Overload Syndrome (FOS), which occurs when the infusion rate exceeds the body’s capacity to clear the fat from the circulation. Regulatory labeling describes FOS presentations through a cluster of systemic signs, which may include fever, chills, nausea, vomiting, dyspnea (difficulty breathing), and clinical signs such as Hepatomegaly or Splenomegaly.

This severe condition may lead to potentially life-threatening outcomes, including Metabolic Acidosis and Coagulopathy (a blood clotting disorder). Regulatory documents specifically note that neonates and infants have a reduced capacity for lipid elimination and are at heightened risk for serious metabolic disturbances following rapid administration.

The governing regulatory guidance is explicit that the infusion must be stopped immediately if any signs of Fat Overload Syndrome are observed. Due to the severe nature of the documented complications, individuals must seek immediate medical attention when these manifestations appear. No specific antidote is known for this overdose. Therefore, management is symptomatic and supportive treatment, with mandatory monitoring of the plasma triglyceride concentration to confirm that the excess lipid has been cleared from the circulation.

Therapeutic Uses of Celepid 10%

Celepid 10% is generally considered relevant in contexts marked by increased systemic imbalance or tension. It is commonly used as a necessary component of specialized nutritional support for individuals requiring assistance with their dietary intake. This support is applicable within clinical settings that involve acute or disruptive symptom patterns.

Its primary uses include providing important nutritional support, assisting with systemic imbalance, and managing symptoms related to Essential Fatty Acid Deficiency (EFAD). It is relevant in clinical settings when supportive nutritional management is appropriate, especially during periods of increased physiological stress.

“It supports general well-being during symptomatic phases.”

It helps address symptoms related to systemic imbalance, supporting functional stability when appropriate. It is commonly used across conditions where symptoms may intensify temporarily, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Systemic Imbalance

Eligibility and Restrictions for Use

Celepid 10% (a lipid emulsion similar to Intralipid and others, often containing soybean oil and lecithin) is typically administered as a source of calories and essential fatty acids in patients who require intravenous nutrition. It is often used to prevent or correct essential fatty acid deficiency in individuals unable to consume adequate oral or enteral nutrition. In some regions, its use may be noted for conditions like nutritional deficiencies, liver disease, or certain neurological conditions.

Who Cannot Use Celepid 10%?

Celepid 10% is contraindicated and should not be used in individuals with the following conditions:

Condition	Reason for Restriction
Hypersensitivity	Known allergy or severe reaction to egg, soybean, peanut, or any component of the formulation.
Severe Lipid Metabolism Disorders	Conditions characterized by severe hypertriglyceridemia (very high levels of fat in the blood, often defined as serum triglycerides greater than 1,000 mg/dL).
Acute Shock	Used with caution or contraindicated in acute shock or conditions involving severely disordered fat metabolism (e.g., severe liver impairment).

Important Considerations

Patients with impaired lipid metabolism (due to conditions like diabetes, obesity, or inherited disorders) should be carefully monitored. Safety data is often limited for use during pregnancy and in patients with severe kidney disease, requiring careful medical consultation before use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Celepid 10% (Intravenous Fat Emulsion) is structured by its documented effects on co-administered substances and strict rules governing its physical compatibility with other intravenous solutions. All interaction statements are derived directly from government-approved labeling.

Pharmacodynamic Interaction Pattern

Interacting Substance Category	Official Interaction Description	Regulatory Constraint
Vitamin K Antagonists (e.g., Warfarin)	The natural Vitamin K1 content from the soybean oil may counteract the anticoagulant activity of coumarin derivatives.	Increased monitoring of coagulation parameters is required to manage the altered effect.

Physical Compatibility and Administration Restrictions

The stability of the emulsion dictates specific constraints for mixing with other additives, ensuring the integrity of the solution during administration.

Incompatible Additives: The emulsion must not be combined with solutions that induce physical instability. This includes highly acidic solutions (pH below 5) and those with inappropriate concentrations of divalent cations ( Ca^++ and Mg^++). Such combinations risk emulsion destabilization which may lead to precipitation.
Specific Drug Separation: The simultaneous co-administration of Ceftriaxone with calcium-containing parenteral nutrition (which incorporates the fat emulsion) is restricted. Administration must be sequential and include thorough line flushing.

Population-Dependent Interaction

Renal Impairment: A specific caution is documented for patients with impaired kidney function. Prolonged parenteral administration of the product carries an increased risk of Aluminum accumulation and toxicity in this population, particularly preterm neonates.

Mechanism of Action

Energy Generation and Core Metabolic Support

The mechanism of Celepid 10% is defined by nutritional substrate provision. The Triglycerides act as a direct substrate for the enzyme Lipoprotein Lipase (LPL), initiating the breakdown into Free Fatty Acids (FFAs). These FFAs enter the mitochondrial beta-oxidation pathway within cells, leading to a massive release of Adenosine Triphosphate (ATP). This process contributes to core energy homeostasis and provides high-yield substrate to meet caloric demand.

Cellular Structure Maintenance and Signaling Precursors

This domain covers the structural role of the ingredients. The Essential Fatty Acids (EFAs) are directly integrated into the cell membrane phospholipid bilayer, which is required for cellular structure and functional integrity. Additionally, EFAs act as precursors for enzymes to create signaling molecules like eicosanoids, influencing the modulation of localized physiological responses.

Coordinated Multi-Substrate Delivery

The emulsion's components act synergistically. Glycerol, released during fat breakdown, serves as an additional substrate that the liver uses in the gluconeogenesis pathway to complement the energy supply with glucose. The coordinated delivery of energy substrates (fat and potential glucose) and structural components (EFAs) participates in systemic metabolic regulation.

Dosage and Administration Information

How to Use Celepid 10% (Intravenous Fat Emulsion 10%)

The usage instructions for Celepid 10% detail the highly controlled manner in which this Nutritional Supplement is administered as a component of parenteral nutrition. Administration is exclusively via a continuous intravenous infusion over a period typically spanning 12 to 24 hours daily.

Administration and Dosing Protocols

The emulsion may be infused into a central vein or a peripheral vein. However, if Celepid 10% is mixed into a Total Nutrient Admixture (TNA), and the final solution's concentration reaches or exceeds 900 mOsm/L, a central vein must be used for administration.

Dosing is calculated based on grams of fat per kilogram of body weight (g/kg/day). For stable adult patients, the maximum daily dosage of fat must not exceed 2.5 g/kg/day. The maximum rate of infusion for adults is limited to 0.1 g/kg/hour. On the first day of therapy, the infused volume of the 10% emulsion is generally limited to 500 mL for initial tolerance assessment.

Preparation and Procedural Constraints

The process requires specific handling. When preparing a TNA, the fat emulsion component must be the last solution added to the mixture of dextrose and amino acids to maintain the emulsion's stability. Furthermore, administration must utilize a 1.2 micron in-line filter, and the container should be visually inspected immediately before use for any signs of phase separation or particulates.

For neonates and infants (up to 2 years of age), the maximum infusion rate is more restrictive, not to exceed 1.0 mL/kg/hour of the 10% emulsion. The duration of therapy is considered long-term, typically used for patients requiring parenteral nutrition for more than five days. Dosage adjustment logic is dependent on the patient's monitored ability to clear the infused fat from the bloodstream, usually confirmed through serum triglyceride levels.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Celepid 10%

Celepid 10% is an intravenous fat emulsion that was studied for use as a source of energy and essential nutrients. This overview summarizes findings described in official regulatory documents and peer-reviewed scientific literature.

Evidence for Foundational Nutritional Support

Research explored the use of this emulsion as a source of basic nutritional support. The earliest evidence used historical control studies and early prospective studies that focused on outcomes such as tracking a patient's caloric intake and monitoring measures like nitrogen balance and weight changes.

Findings indicate the emulsion provided a source of fat and calories to patients whose nutritional needs was observed in these research contexts. Studies monitored the use of the product as a nutritional supplement for both adults and children receiving intravenous feeding. This means that few data are available for long-term functional outcomes solely related to this specific emulsion type.

Research on Essential Fatty Acid Deficiency (EFAD) Correction

This product was evaluated in studies examining its potential for the prevention or correction of a specific nutritional problem known as Essential Fatty Acid Deficiency (EFAD). The outcomes monitored were centered on the Triene:Tetraene (T:T) ratio reaching a defined target range.

Studies describe short-term changes, monitoring how this specific biochemical marker evolved in the observed populations. Data for long-term functional patient outcomes following the observed change in the deficiency marker remain insufficient.

Comparative Studies in Critically Ill Patients

Research examined this specific soybean oil-only emulsion in studies alongside newer-generation multi-oil fat emulsions. The research tracked important clinical outcomes such as mortality, length of hospital stay (LOS), and the duration of mechanical ventilation. Findings from these comparative trials were mixed and often showed variability across different studies for major clinical endpoints. The evidence quality varies across studies, and sample sizes were modest.

Evidence in Vulnerable and Special Populations

Specific research has been conducted for vulnerable groups, particularly neonates and premature infants, who often require long-term intravenous nutritional support. Studies monitored outcomes such as growth parameters and the potential development of liver disease (measured by bilirubin levels). Research describes that prolonged use was associated with the monitoring of liver function markers (PNALD) in this vulnerable population in some observational studies.

Key Uncertainties and Research Gaps

The evidence landscape, while contributing to the understanding of the product's nutritional role, presents several areas where research is ongoing. Comparative evidence is lacking in terms of absolute superiority for clinical endpoints. Long-term effects are not fully established, and follow-up durations were limited in many key studies. Results apply only to the populations studied and findings describe group patterns, not personal outcomes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Celepid 10% (FAQ)

Q: What are the most common side effects of Celepid 10%?

A: Official clinical trial data provides a list of common adverse reactions. These effects, which were reported in more than 1% of patients, include nausea, vomiting, fever (pyrexia), high blood pressure (hypertension), and headache. However, individual experience with side effects can vary.

Q: Can Celepid 10% be taken with vitamins or supplements?

A: The official product information describes that this intravenous fat emulsion may be used in admixtures (mixtures of nutritional solutions) that contain both vitamins and trace elements. Specific precautions are noted, such as protecting the solution from light, particularly when these mixtures are used for very young children.

Q: What should I do if a side effect seems serious?

A: Official regulatory guidance addresses how to handle serious events, such as a severe allergic reaction or fat overload syndrome. If signs of a serious reaction are noticed, the infusion should be stopped immediately. Regulatory guidance specifies that the patient's care team or doctor must be contacted immediately.

Q: Does taking Celepid 10% require special monitoring or tests?

A: Yes, regulatory standards require certain monitoring procedures. This includes checking the patient’s ability to clear fat from the bloodstream, which is typically confirmed by monitoring serum triglyceride levels. Liver function markers are also monitored to track potential liver changes that may be associated with prolonged use.

Q: Can pregnant or breastfeeding individuals use Celepid 10%?

A: Official documents state that the medicine should only be administered during pregnancy if it is considered clearly needed. Furthermore, caution is advised by regulatory authorities when the product is administered to an individual who is nursing or breastfeeding.

Q: Does Celepid 10% affect blood sugar levels?

A: Clinical data indicates that the administration of intravenous fat emulsions can affect the body’s ability to produce glucose, a process known as gluconeogenesis. Elevated blood sugar (hyperglycemia) was also reported as an adverse reaction in some clinical studies, indicating that monitoring of blood sugar may be necessary.

Q: Is Celepid 10% the same as other medicines for the same condition?

A: Celepid 10% is one specific product within the pharmacological class of Intravenous Fat Emulsions (IVFEs). Official documents confirm that other formulations, such as different types of fat emulsions, are also used for the same nutritional purpose.

Q: Is it normal to feel tired after starting Celepid 10%?

A: Official regulatory reports have included notes on effects such as tiredness and drowsiness. These effects have been observed in some individuals immediately or soon after the infusion has commenced.

Q: Can I use Celepid 10% if I have kidney issues?

A: Official warnings state that patients with impaired kidney function should use the product with caution. This is primarily due to a documented risk of aluminum accumulation and toxicity, particularly when the medicine is used for prolonged periods.

Q: How long can a person stay on Celepid 10%?

A: The product is indicated for use over extended periods of time, usually defined as more than 5 days. For use exceeding two weeks, specific monitoring is noted as necessary, especially in children, due to the risk of conditions like Parenteral Nutrition-Associated Liver Disease (PNALD).

Q: Does Celepid 10% affect sleep?

A: Adverse reaction reports documented in regulatory files have included 'trouble sleeping' (insomnia) as one of the side effects that may occur during the use of this product.

Q: Is there a specific time of day when Celepid 10% is usually taken?

A: According to official administration protocols, the daily dose of the emulsion is preferably administered as a continuous infusion. This infusion is typically administered over a 24-hour period using an infusion pump.

Q: Are there long-term side effects associated with Celepid 10%?

A: Yes, official warnings address risks associated with prolonged administration, which is defined as use extending beyond two weeks. These risks include the potential for Parenteral Nutrition-Associated Liver Disease (PNALD) and aluminum toxicity, particularly in patients with kidney impairment.

Q: Why does the official document mention a risk of [specific non-serious side effect]?

A: Official labeling documents are required by regulatory authorities to provide a comprehensive list of all adverse events and reactions that were observed in studies or post-marketing surveillance. This ensures that the documentation is complete for healthcare professionals and patients, regardless of the severity of the effect.

Q: What are the signs that Celepid 10% is working?

A: The product is indicated as a source of energy and essential fatty acids. Its purpose is to prevent or correct the clinical and biochemical signs of Essential Fatty Acid Deficiency (EFAD) in patients who cannot receive adequate nutrition through other routes.

Q: Is Celepid 10% related to any common substances I should know about?

A: The emulsion is primarily composed of common substances including Soybean Oil, Egg Yolk Phospholipids, and Glycerin. Because of its components, official warnings note that the product is strictly contraindicated in patients with a known hypersensitivity (allergy) to egg, soybean, or peanut protein.

Q: Is Celepid 10% available over the counter?

A: This medicine is defined as a sterile intravenous emulsion that is administered as a continuous infusion in a clinical or hospital setting. Due to this specialized route of administration, it is not available for purchase over the counter.

Q: Can I drive while taking Celepid 10%?

A: The official regulatory document states that no effects on the ability to drive and operate machines are to be expected.

Q: Are there specific symptoms that mean I should stop taking Celepid 10%?

A: Yes, official regulatory guidance indicates that the infusion should be stopped immediately if signs of a hypersensitivity reaction (allergic reaction) or signs of fat overload syndrome occur.

Q: Does Celepid 10% affect mood or mental state?

A: Some adverse reaction reports submitted to regulatory bodies have included terms related to changes in mood or mental state such as confusion and drowsiness.

Q: Do official sources describe Celepid 10% as having a rapid effect?

A: The product is indicated for use over extended periods of time, usually more than 5 days, and the infusion is administered slowly, preferably continuously over 24 hours. This administration approach does not align with the description of a rapid-acting effect.

Q: Can children or teenagers use Celepid 10%?

A: Yes, official regulatory documents include specific dosing, infusion rate, and monitoring requirements for pediatric patients, covering neonates, infants, and children.

How should Celepid 10% be stored and disposed of?

Storage and Disposal for Intralipid 10% (Intravenous Fat Emulsion)

Storage and disposal requirements for Intralipid 10% are strictly defined in official regulatory documents to maintain product quality and safety.

Condition	Regulatory Requirement
Unopened Temperature	Store below 25 C (77 F); Do not freeze
Child Safety	Must be kept out of the reach of children
Light Protection	Protect from light during administration for neonates and children below 2 years of age

After removing the overpouch, the product should be used immediately. If immediate use is not possible, storage at 2 C to 8 C is limited to a maximum of 24 hours. The contents of a Pharmacy Bulk Package must be used within 4 hours after the closure is penetrated. Any unused medicine or waste material must be discarded in accordance with local requirements.

Celepid 10%